Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 58.87 USD 1.1% Market Closed
Market Cap: 119.4B USD
Have any thoughts about
Bristol-Myers Squibb Co?
Write Note

Bristol-Myers Squibb Co
Unrealized Security Profit/Loss

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bristol-Myers Squibb Co
Unrealized Security Profit/Loss Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Unrealized Security Profit/Loss CAGR 3Y CAGR 5Y CAGR 10Y
Bristol-Myers Squibb Co
NYSE:BMY
Unrealized Security Profit/Loss
$5m
CAGR 3-Years
8%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Unrealized Security Profit/Loss
$1m
CAGR 3-Years
N/A
CAGR 5-Years
0%
CAGR 10-Years
-38%
Pfizer Inc
NYSE:PFE
Unrealized Security Profit/Loss
-$1m
CAGR 3-Years
81%
CAGR 5-Years
N/A
CAGR 10-Years
35%
Merck & Co Inc
NYSE:MRK
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zoetis Inc
NYSE:ZTS
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eli Lilly and Co
NYSE:LLY
Unrealized Security Profit/Loss
-$16.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Bristol-Myers Squibb Co
Glance View

Market Cap
119.4B USD
Industry
Pharmaceuticals

Bristol-Myers Squibb Co. (BMS) is a global biopharmaceutical company renowned for its innovative approach to discovering and developing transformative medicines. Founded over 160 years ago, BMS has built a robust portfolio that includes therapies across oncology, immunology, cardiovascular disease, and infectious diseases, focusing on addressing unmet medical needs. The company is celebrated for its substantial investments in research and development, which have led to groundbreaking treatments like Opdivo and Eliquis. These products have not only propelled revenue growth but also established BMS as a key player in the life sciences sector, showcasing its commitment to advancing the health and well-being of patients around the world. For investors, BMS presents a compelling opportunity rooted in a strong pipeline and strategic partnerships. The company has navigated recent challenges, including patent expirations, by fostering innovation and expanding its therapeutic offerings through mergers and acquisitions. In the ever-evolving healthcare landscape, BMS aims to leverage its scientific expertise and market presence to drive sustainable growth. With a focus on maintaining a balanced portfolio and a disciplined approach to capital allocation, Bristol-Myers Squibb stands out as a resilient entity poised to deliver long-term value, supported by a robust pipeline expected to bring additional blockbuster products to market in the coming years.

BMY Intrinsic Value
71 USD
Undervaluation 17%
Intrinsic Value
Price

See Also

What is Bristol-Myers Squibb Co's Unrealized Security Profit/Loss?
Unrealized Security Profit/Loss
5m USD

Based on the financial report for Sep 30, 2024, Bristol-Myers Squibb Co's Unrealized Security Profit/Loss amounts to 5m USD.

What is Bristol-Myers Squibb Co's Unrealized Security Profit/Loss growth rate?
Unrealized Security Profit/Loss CAGR 5Y
-17%

The average annual Unrealized Security Profit/Loss growth rates for Bristol-Myers Squibb Co have been 8% over the past three years , -17% over the past five years .

Back to Top